Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

FDA approves first biosimilar to Roche cancer drug Rituxan

November 29, 2018 12:49 AM
160 0

(Reuters) - Celltrion Inc’s Truxima on Wednesday became the first biosimilar to Roche Holding AG’s $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin’s lymphoma.

The approval by the U.S. Food and Drug Administration is part of the agency’s plan to encourage development of cheaper biosimilars amid rising prices of prescription medicines.

Read more

Share in social networks:

Comments - 0